{"organizations": [], "uuid": "698f9e5b82fea9e73c7fb74522c43a844ef05952", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-resverlogix-exceeds-full-enrollmen/brief-resverlogix-exceeds-full-enrollment-for-the-pivotal-phase-3-betonmace-clinical-trial-idUSASC09SQZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T13:14:00.000+02:00", "replies_count": 0, "uuid": "698f9e5b82fea9e73c7fb74522c43a844ef05952"}, "author": "", "url": "https://www.reuters.com/article/brief-resverlogix-exceeds-full-enrollmen/brief-resverlogix-exceeds-full-enrollment-for-the-pivotal-phase-3-betonmace-clinical-trial-idUSASC09SQZ", "ord_in_thread": 0, "title": "BRIEF-Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [{"name": "betonmace", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "resverlogix corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 17 AM / Updated 7 minutes ago BRIEF-Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial Reuters Staff March 19 (Reuters) - Resverlogix Corp: * RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL * RESVERLOGIX CORP - EXPLORING OPTION OF US ENROLLMENT IN BETONMACE TRIAL AS WELL AS OPTION OF RELYING ON EXISTING BETONMACE DATA TO FILE A US NDA * RESVERLOGIX CORP - ‍ PRIMARY ENDPOINT READ-OUT OF ONGOING PHASE 3 BETONMACE TRIAL AROUND END OF 2018​ Source text for Eikon:  ", "external_links": [], "published": "2018-03-19T13:14:00.000+02:00", "crawled": "2018-03-19T13:27:47.026+02:00", "highlightTitle": ""}